Cargando…

2811. Real-World Experience Utilizing Cefiderocol for Serious Multidrug Resistant Gram-Negative Infections

BACKGROUND: Cefiderocol is a novel siderophore cephalosporin that demonstrated in vitro activity against carbapenem-resistant Enterobacterales, Acinetobacter baumannii (AB), Pseudomonas aeruginosa (PA), and Stenotrophomonas maltophilia. Cefiderocol demonstrated promising efficacy in randomized, clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teran, Nicholas S, Zidaru, Andrei, Phe, Kady
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679052/ http://dx.doi.org/10.1093/ofid/ofad500.2422

Ejemplares similares

200. Comparison of Clinical Outcomes among Patients Treated with Ceftriaxone 2 Grams versus 1 Gram Daily for Gram-Negative Bacteremia
por: Huynh-Phan, Ricky, et al.
Publicado: (2023)

239. Comparing Alternative Treatment Options for Stenotrophomonas maltophilia bacteremia
por: Teran, Nicholas S, et al.
Publicado: (2023)

1624. Real World Experience with Daptomycin (DAP) and Ceftaroline (CPT) Combination Therapy for Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia
por: Zidaru, Andrei, et al.
Publicado: (2020)

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

640. A Retrospective Assessment of the Effects of Cefiderocol in Patients with Multidrug-resistant Gram-negative Bacterial Infections
por: Sajib, Monirul I, et al.
Publicado: (2022)

Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

P35 Heteroresistance to cefiderocol in clinical Gram-negative isolates
por: Watson, Celeste, et al.
Publicado: (2023)

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
por: Pybus, Christine A., et al.
Publicado: (2021)

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
por: Wu, Janet Y., et al.
Publicado: (2020)

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria
por: Silva, José Tiago, et al.
Publicado: (2021)

719. Cefiderocol Retains Anti-Biofilm Activity in MDR Gram-Negative Pathogens
por: Pybus, Christine A, et al.
Publicado: (2019)

2753. Real-World Use of Cefiderocol Treating Non-COVID Patients with Confirmed Gram-Negative Infections in US Hospitals During January 2020-June 2022
por: Cai, Bin, et al.
Publicado: (2023)

1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
por: Matsunaga, Yuko, et al.
Publicado: (2020)

2021. Efficacy of Chronic Antimicrobial Suppressive Therapy in Ventricular Assist Device Infections
por: Teran, Nicholas S, et al.
Publicado: (2022)

1291. PROVE (Retrospective Cefiderocol Chart Review) Study of Real-World Outcomes and Safety in the Treatment of Patients with Gram-negative Bacterial Infections in the US and Europe
por: Marcella, Stephen, et al.
Publicado: (2021)

Real-world experience with cefiderocol therapy for Pseudomonas aeruginosa and other multidrug resistant gram-negative infections within the Veterans Health Administration, 2019–2022
por: Chou, Andrew, et al.
Publicado: (2023)

In Vitro Activity of Cefiderocol against Multi-Drug Resistant Carbapenemase-Producing Gram-Negative Pathogens
por: Boyd, Sandra, et al.
Publicado: (2017)

648. Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections
por: Chou, Andrew, et al.
Publicado: (2022)

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
por: Mushtaq, Shazad, et al.
Publicado: (2020)

Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2020)

1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients
por: Rolston, Kenneth V I, et al.
Publicado: (2018)

721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
por: Iregui, Alejandro, et al.
Publicado: (2019)

2118. Comparative Analysis of Cefiderocol Mono- and Combination Therapy for Multi-Drug Resistant Gram-negative Infections
por: Ghali, Amer El, et al.
Publicado: (2023)

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
por: Wang, Chuanhai, et al.
Publicado: (2022)

In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

P43 In vitro activity of cefiderocol and comparators against Gram-negative pathogens: ARTEMIS study in the UK
por: Wareham, D., et al.
Publicado: (2022)

1308. Activity of Cefiderocol and Comparators against Gram-negative Isolates from US Patients Hospitalized with Pneumonia
por: Shortridge, Dee, et al.
Publicado: (2021)

Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
por: Frontiers Production Office,
Publicado: (2022)

1349. Global Surveillance of Cefiderocol Against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015
por: Tsuji, Masakatsu, et al.
Publicado: (2018)

1544. Efficacy of Human-Simulated Cefiderocol Exposure Against Gram-Negative Bacteria in an Iron-Overloaded Murine Thigh Infection Model
por: Kidd, James M, et al.
Publicado: (2019)

144. Gram Negative Bacteria with Increased Minimal Inhibitory Concentration for Cefiderocol among Pediatric Patients in a Northern Italy Hospital.
por: Russo, Chiara, et al.
Publicado: (2022)

1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study
por: Bassetti, Matteo, et al.
Publicado: (2020)

Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature
por: Zingg, Sandra, et al.
Publicado: (2020)

Performance evaluation of the UMIC(®) Cefiderocol to determine MIC in Gram-negative bacteria
por: Dortet, Laurent, et al.
Publicado: (2023)

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

In Vivo Efficacy of Humanized Exposures of Cefiderocol Compared with Cefepime (FEP) and Meropenem (MEM) against Gram-negative Bacteria in a Murine Thigh Model
por: Monogue, Marguerite, et al.
Publicado: (2017)

1734. Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021
por: Kung, Frank H, et al.
Publicado: (2022)

666. Outcomes Using Cefiderocol for the Treatment of Acinetobacter baumannii Infections from the PROVE (Real-World Evidence) Study
por: Marcella, Stephen, et al.
Publicado: (2022)

Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience
por: Piccica, Matteo, et al.
Publicado: (2023)

1998. Impact of Rapid Blood Culture Identification with Real-Time Antimicrobial Stewardship (ASP) in Patients with Staphylococcus aureus (S. aureus) and Enterococcus spp. Bacteremia at a Large Academic Medical Center
por: Ryan Russo, Hannah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bpsspk3u5htsuthg90hd9u4fcq